FPH Share Price Performance
NZ$0
-36.41 (-100.00%)
Price NZ$0
Fair ValueNZ$47.00
Share Pricen/a
Narrative Update • Jul 22
Fisher & Paykel Healthcare Corporation Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 38 Fair Values set on narratives written by author
FPH Community Narratives
AN
Fair Value
·Fair Value NZ$47 15.1% undervalued intrinsic discount
Respiratory Therapy Adoption Will Drive Stronger Margins And Support Long Term Upside
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value NZ$39.75 0.4% overvalued intrinsic discount
Analysts Hold Price Target for Fisher and Paykel Healthcare as Valuation Inputs Remain Stable
0users have liked this narrative
0users have commented on this narrative
19users have followed this narrative
AN
Fair Value
·Fair Value NZ$30.59 30.4% overvalued intrinsic discount
Tariff Pressures And Slowing Hospital Adoption Will Constrain Long-Term Earnings Trajectory
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Tariff Pressures And Slowing Hospital Adoption Will Constrain Long-Term Earnings Trajectory
Fisher & Paykel Healthcare faces a tougher road ahead as trade tariffs, rising investment needs, and slower hospital rollout threaten to blunt its long-term profit growth. The key question is whether stronger respiratory-care demand and efficiency gains can keep momentum going despite tougher competition and cost pressure.Read more
AN
NZ$30.59
30.4% overvalued intrinsic discount
Fair Value
Revenue
10.32% p.a.
Profit Margin
22.84%
Future PE
31.55x
Price in 2029
NZ$38.12
Respiratory Therapy Adoption Will Drive Stronger Margins And Support Long Term Upside
Fisher & Paykel Healthcare could benefit as more hospitals and home patients adopt its breathing therapies and masks, which may drive repeat sales of consumables and improve profits over time. The main questions are whether demand stays strong through changing flu seasons, tariffs, and shifting health-insurance rules—especially in the U.S.Read more
AN
NZ$47
15.1% undervalued intrinsic discount
Fair Value
Revenue
13.53% p.a.
Profit Margin
25.23%
Future PE
40.35x
Price in 2029
NZ$58.67
Analysts Hold Price Target for Fisher and Paykel Healthcare as Valuation Inputs Remain Stable
Fisher & Paykel Healthcare looks set to benefit from an aging population and growing need for breathing and sleep-related care, helped by a steady stream of new devices for hospitals and home use. But the upside depends on hospitals keeping spending power and on the company defending its pricing against trade costs, currency swings, and tougher competition.Read more
AN
NZ$39.75
0.4% overvalued intrinsic discount
Fair Value
Revenue
11.07% p.a.
Profit Margin
23.73%
Future PE
38.74x
Price in 2029
NZ$49.62
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
FPH: Removal From Conviction List Will Pressure Overvalued Shares
Fair Value: NZ$30.59 30.4% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
FPH: Removal From Conviction List Will Meet Higher Dividend Outlook
Fair Value: NZ$47 15.1% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
FPH: Stable Dividend And Earnings Outlook Will Support Measured Future Repricing
Fair Value: NZ$39.75 0.4% overvalued intrinsic discount
19 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Fisher & Paykel Healthcare Corporation Limited Key Details
About FPH
- Founded
- 1934
- Employees
- 7396
- CEO
- WebsiteView website
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. The company provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. It also offers adult respiratory products, including airvo system, optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilation. In addition, the company provides infant respiratory products, such as resuscitation, invasive ventilation, continuous positive airway pressure (CPAP), and nasal high flow products. Further, it offers hospital products comprising humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, and humidifiers. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.
Recent FPH News & Updates
Narrative Update • Jul 08
FPH: Removal From Conviction List Will Meet Higher Dividend Outlook
Analysts have modestly raised the fair value estimate for Fisher & Paykel Healthcare from NZ$46.00 to NZ$47.00, citing updated assumptions on revenue growth, profit margins, and future P/E multiples, along with the stock's recent removal from an APAC Conviction List. What's in the News for Fisher & Paykel Healthcare Fisher & Paykel Healthcare Corporation Limited announced a dividend of NZ$0.38823529 per share for the six months ended March 31, 2026.
Narrative Update • Jun 24
